What is Ilotycin and how is it used?
Ilotycin is a prescription medicine used to treat the symptoms of Conjunctivitis. Ilotycin may be used alone or with other medications.
Ilotycin belongs to a class of drugs called Macrolides, Ophthalmic.
What are the possible side effects of Ilotycin?
Ilotycin may cause serious side effects including:
- new or worsening eye symptoms (pain, swelling, thick discharge or pus),
- swelling of the face, tongue or throat,
- severe dizziness, and
- trouble breathing
Get medical help right away, if you have any of the symptoms listed above.
The most common side effects of Ilotycin include:
- minor eye irritations,
- temporary blurred vision, and
- hypersensitivity reactions
Tell the doctor if you have any side effect that bothers you or that does not go away.
These are not all the possible side effects of Ilotycin. For more information, ask your doctor or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
ILOTYCIN™ Erythromycin Ophthalmic Ointment belongs to the macrolide group of antibiotics. It is basic and readily forms a salt when combined with an acid. The base, as crystals or powder, is slightly soluble in water, moderately soluble in ether, and readily soluble in alcohol or chloroform. Erythromycin ((3R*, 4S*, 5S*, 6R*, 7R*, 9R*, 11R*, 12R*, 13S*, 14R*) -4-[(2,6-dideoxy-3-C-methyl-3-0-methyl-α-L-ribo-hexopyranosyl)oxy]-14-ethyl-7, 12,13-trihydroxy-3, 5, 7, 9, 11, 13-hexamethyl-6-[[3, 4, 6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]oxacyclotetradecane-2, 10-dione) is an antibiotic produced from a strain of Streptomyces erythraeus. It has the following structural formula:
Molecular Formula: C37H67NO13
Molecular Weight: 733.94
Each gram contains Erythromycin USP 5 mg in a sterile ophthalmic base of mineral oil and white petrolatum.
3 pharmacies near 20147 have coupons for Eyemycin (Brand Names:Ilotycin for 3.5GM of 5MG/GM)
Est. Regular Price
with free coupon
The effectiveness of erythromycin in the prevention of ophthalmia caused by penicillinase-producing N. gonorrhoeae is not established.
For infants born to mothers with clinically apparent gonorrhea, intravenous or intramuscular injections of aqueous crystalline penicillin G should be given; a single dose of 50,000 units for term infants or 20,000 units for infants of low birth weight. Topical prophylaxis alone is inadequate for these infants.
DOSAGE AND ADMINISTRATION
In the treatment of superficial ocular infections, a ribbon approximately 1 cm in length of ILOTYCIN™ Ophthalmic Ointment should be applied directly to the infected structure up to 6 times daily, depending on the severity of the infection.
For prophylaxis of neonatal gonococcal or chlamydial conjunctivitis, a ribbon of ointment approximately 1 cm in length should be instilled into each lower conjunctival sac. The ointment should not be flushed from the eye following instillation. A new tube should be used for each infant.
Sterile ILOTYCIN™ Ophthalmic Ointment USP, 5 mg/g as follows:
1 g tamper-evident tubes NDC 48102-016-11
Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].
Avoid excessive heat.
Protect from freezing.
Manufactured for: Fera Pharmaceuticals, LLC, Locust Valley, NY 11560. Rev. 06/10
The most frequently reported adverse reactions are minor ocular irritations, redness, and hypersensitivity reactions.
To report SUSPECTED ADVERSE REACTIONS, contact Fera Pharmaceuticals, LLC at (414) 434-6604 Monday-Friday 9am-5pm EST or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
No information provided.
No information provided.
The use of antimicrobial agents may be associated with the overgrowth of nonsusceptible organisms including fungi; in such a case, antibiotic administration should be stopped and appropriate measures taken.
Carcinogenesis, Mutagenesis, Impairment of Fertility
Two year oral studies conducted in rats with erythromycin did not provide evidence of tumorigenicity. Mutagenicity studies have not been conducted. No evidence of impaired fertility that appeared related to erythromycin was reported in animal studies.
Teratogenic effects -Pregnancy category B
Reproduction studies have been performed in rats, mice, and rabbits using erythromycin and its various salts and esters, at doses that were several multiples of the usual human dose. No evidence of harm to the fetus that appeared related to erythromycin was reported in these studies. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproductive studies are not always predictive of human response, the erythromycins should be used during pregnancy only if clearly needed.
Caution should be exercised when erythromycin is administered to a nursing woman.
No information provided.
This drug is contraindicated in patients with a history of hypersensitivity to erythromycin.
Streptococcus pyogenes (group A β-hemolytic)
Alpha-hemolytic streptococci (viridans group)
Staphylococcus aureus, including penicillinase-producing strains (methicillin-resistant staphylococci are uniformly resistant to erythromycin)
Mycoplasma pneumoniae (Eaton Agent, PPLO)
Haemophilus influenzae (not all strains of this organism are susceptible at the erythromycin concentrations ordinarily achieved)
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.